1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	objective	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	paper	_	_	NN	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	using	_	_	VBG	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	Essential	_	_	NNP	_	_	_	_	_
10	Medicines	_	_	NNP	_	_	_	_	_
11	List	_	_	NNP	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	children	_	_	NNS	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	World	_	_	NNP	_	_	_	_	_
17	Health	_	_	NNP	_	_	_	_	_
18	Organization	_	_	NNP	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	WHO	_	_	NNP	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	create	_	_	VB	_	_	_	_	_
24	a	_	_	DT	_	_	_	_	_
25	provisional	_	_	JJ	_	_	_	_	_
26	pediatric	_	_	JJ	_	_	_	_	_
27	biopharmaceutics	_	_	NN	_	_	_	_	_
28	classification	_	_	NN	_	_	_	_	_
29	system	_	_	NN	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	pBCS	_	_	NNP	_	_	_	_	_
32	)	_	_	-RRB-	_	_	_	_	_
33	for	_	_	IN	_	_	_	_	_
34	oral	_	_	JJ	_	_	_	_	_
35	drugs	_	_	NNS	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	to	_	_	TO	_	_	_	_	_
38	compare	_	_	VB	_	_	_	_	_
39	our	_	_	PRP$	_	_	_	_	_
40	results	_	_	NNS	_	_	_	_	_
41	with	_	_	IN	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	BCS	_	_	NNP	_	_	_	_	_
44	for	_	_	IN	_	_	_	_	_
45	adults	_	_	NNS	_	_	_	_	_
46	(	_	_	-LRB-	_	_	_	_	_
47	aBCS	_	_	NNP	_	_	_	_	_
48	)	_	_	-RRB-	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	Since	_	_	IN	_	_	_	_	_
2	2007	_	_	CD	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	WHO	_	_	NNP	_	_	_	_	_
6	has	_	_	VBZ	_	_	_	_	_
7	provided	_	_	VBN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	WHO	_	_	NNP	_	_	_	_	_
10	Model	_	_	NNP	_	_	_	_	_
11	List	_	_	NNP	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	Essential	_	_	NNP	_	_	_	_	_
14	Medicines	_	_	NNPS	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	Children	_	_	NNPS	_	_	_	_	_
17	;	_	_	:	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	core	_	_	JJ	_	_	_	_	_
20	drug	_	_	NN	_	_	_	_	_
21	list	_	_	NN	_	_	_	_	_
22	for	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	basic	_	_	JJ	_	_	_	_	_
25	health-care	_	_	NN	_	_	_	_	_
26	system	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	resource	_	_	NN	_	_	_	_	_
3	list	_	_	NN	_	_	_	_	_
4	considers	_	_	VBZ	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	safest	_	_	JJS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	efficacious	_	_	JJ	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	cost-effective	_	_	JJ	_	_	_	_	_
11	drugs	_	_	NNS	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	priority	_	_	NN	_	_	_	_	_
14	pathologies	_	_	NNS	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	pediatrics	_	_	NNS	_	_	_	_	_
17	up	_	_	IN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	12	_	_	CD	_	_	_	_	_
20	years	_	_	NNS	_	_	_	_	_
21	old	_	_	JJ	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	All	_	_	DT	_	_	_	_	_
2	immediate	_	_	JJ	_	_	_	_	_
3	release	_	_	NN	_	_	_	_	_
4	oral	_	_	JJ	_	_	_	_	_
5	drugs	_	_	NNS	_	_	_	_	_
6	from	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	sixth	_	_	JJ	_	_	_	_	_
9	edition	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	this	_	_	DT	_	_	_	_	_
12	list	_	_	NN	_	_	_	_	_
13	were	_	_	VBD	_	_	_	_	_
14	selected	_	_	VBN	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	this	_	_	DT	_	_	_	_	_
17	work	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	need	_	_	NN	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	importance	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	developing	_	_	VBG	_	_	_	_	_
8	appropriate	_	_	JJ	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	safe	_	_	JJ	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	effective	_	_	JJ	_	_	_	_	_
13	medicines	_	_	NNS	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	pediatrics	_	_	NNS	_	_	_	_	_
16	have	_	_	VBP	_	_	_	_	_
17	now	_	_	RB	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	recognized	_	_	VBN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Pediatrics	_	_	NN	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	long	_	_	RB	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	considered	_	_	VBN	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	therapeutically	_	_	RB	_	_	_	_	_
9	disregarded	_	_	VBN	_	_	_	_	_
10	group	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	fact	_	_	NN	_	_	_	_	_
3	lies	_	_	VBZ	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	therapeutic	_	_	JJ	_	_	_	_	_
7	gap	_	_	NN	_	_	_	_	_
8	that	_	_	WDT	_	_	_	_	_
9	originates	_	_	VBZ	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	formulation	_	_	NN	_	_	_	_	_
12	development	_	_	NN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	mainly	_	_	RB	_	_	_	_	_
15	focused	_	_	VBN	_	_	_	_	_
16	on	_	_	IN	_	_	_	_	_
17	adults	_	_	NNS	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	low	_	_	JJ	_	_	_	_	_
21	availability	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	commercial	_	_	JJ	_	_	_	_	_
24	pediatric	_	_	JJ	_	_	_	_	_
25	drugs	_	_	NNS	_	_	_	_	_
26	for	_	_	IN	_	_	_	_	_
27	pediatric	_	_	JJ	_	_	_	_	_
28	use	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	physiological	_	_	JJ	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	anatomical	_	_	JJ	_	_	_	_	_
33	differences	_	_	NNS	_	_	_	_	_
34	relative	_	_	JJ	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	adult	_	_	JJ	_	_	_	_	_
38	population	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	younger	_	_	JJR	_	_	_	_	_
3	pediatrics	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	neonates	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	infants	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	therapeutic-risk	_	_	JJ	_	_	_	_	_
11	benefits	_	_	NNS	_	_	_	_	_
12	associated	_	_	VBN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	drug	_	_	NN	_	_	_	_	_
15	treatment	_	_	NN	_	_	_	_	_
16	may	_	_	MD	_	_	_	_	_
17	be	_	_	VB	_	_	_	_	_
18	different	_	_	JJ	_	_	_	_	_
19	from	_	_	IN	_	_	_	_	_
20	those	_	_	DT	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	adults	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Developmental	_	_	JJ	_	_	_	_	_
2	physiological	_	_	JJ	_	_	_	_	_
3	differences	_	_	NNS	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	composition	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	gastrointestinal	_	_	JJ	_	_	_	_	_
10	fluids	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	presence	_	_	NN	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	activity	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	intestinal	_	_	JJ	_	_	_	_	_
18	drug	_	_	NN	_	_	_	_	_
19	metabolizing	_	_	VBG	_	_	_	_	_
20	enzymes	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	efflux	_	_	NN	_	_	_	_	_
23	transporters	_	_	NNS	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	can	_	_	MD	_	_	_	_	_
26	markedly	_	_	RB	_	_	_	_	_
27	alter	_	_	VB	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	bioavailability	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	drugs	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Age-related	_	_	JJ	_	_	_	_	_
2	changes	_	_	NNS	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	characteristics	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	luminal	_	_	JJ	_	_	_	_	_
8	fluids	_	_	NNS	_	_	_	_	_
9	such	_	_	JJ	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	pH	_	_	NN	_	_	_	_	_
12	may	_	_	MD	_	_	_	_	_
13	lead	_	_	VB	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	changes	_	_	NNS	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	drug	_	_	NN	_	_	_	_	_
18	solubility	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	therefore	_	_	RB	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	absorption	_	_	NN	_	_	_	_	_
25	since	_	_	IN	_	_	_	_	_
26	only	_	_	RB	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	dissolved	_	_	VBN	_	_	_	_	_
29	drug	_	_	NN	_	_	_	_	_
30	would	_	_	MD	_	_	_	_	_
31	be	_	_	VB	_	_	_	_	_
32	available	_	_	JJ	_	_	_	_	_
33	for	_	_	IN	_	_	_	_	_
34	absorption	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Since	_	_	IN	_	_	_	_	_
2	fluctuations	_	_	NNS	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	pH	_	_	NN	_	_	_	_	_
5	may	_	_	MD	_	_	_	_	_
6	influence	_	_	VB	_	_	_	_	_
7	ionizable	_	_	JJ	_	_	_	_	_
8	drugs	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	relative	_	_	JJ	_	_	_	_	_
12	amount	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	unionized	_	_	JJ	_	_	_	_	_
15	available	_	_	JJ	_	_	_	_	_
16	drug	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	there	_	_	EX	_	_	_	_	_
19	could	_	_	MD	_	_	_	_	_
20	be	_	_	VB	_	_	_	_	_
21	changes	_	_	NNS	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	absorption	_	_	NN	_	_	_	_	_
24	during	_	_	IN	_	_	_	_	_
25	maturation	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	gastric	_	_	JJ	_	_	_	_	_
3	pH	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	newborn	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	approximately	_	_	RB	_	_	_	_	_
9	neutral	_	_	JJ	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	within	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	first	_	_	JJ	_	_	_	_	_
15	48	_	_	CD	_	_	_	_	_
16	h	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	life	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	gastrointestinal	_	_	JJ	_	_	_	_	_
22	pH	_	_	NN	_	_	_	_	_
23	decreases	_	_	VBZ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	adult	_	_	JJ	_	_	_	_	_
26	values	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	then	_	_	RB	_	_	_	_	_
29	for	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	first	_	_	JJ	_	_	_	_	_
32	month	_	_	NN	_	_	_	_	_
33	increases	_	_	VBZ	_	_	_	_	_
34	back	_	_	RB	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	values	_	_	NNS	_	_	_	_	_
37	close	_	_	JJ	_	_	_	_	_
38	to	_	_	TO	_	_	_	_	_
39	neutrality	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	After	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	first	_	_	JJ	_	_	_	_	_
4	month	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	gastric	_	_	JJ	_	_	_	_	_
7	pH	_	_	NN	_	_	_	_	_
8	decreases	_	_	VBZ	_	_	_	_	_
9	progressively	_	_	RB	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	reach	_	_	VB	_	_	_	_	_
12	similar	_	_	JJ	_	_	_	_	_
13	values	_	_	NNS	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	adults	_	_	NNS	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	two	_	_	CD	_	_	_	_	_
19	years	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	age	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	other	_	_	JJ	_	_	_	_	_
4	hand	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	another	_	_	DT	_	_	_	_	_
7	determinant	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	bioavailability	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	ontogenic	_	_	JJ	_	_	_	_	_
12	changes	_	_	NNS	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	expression	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	drug	_	_	NN	_	_	_	_	_
18	metabolizing	_	_	VBG	_	_	_	_	_
19	enzymes	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	transporters	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	which	_	_	WDT	_	_	_	_	_
24	would	_	_	MD	_	_	_	_	_
25	mark	_	_	VB	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	first	_	_	JJ	_	_	_	_	_
28	pass	_	_	NN	_	_	_	_	_
29	effect	_	_	NN	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	consequently	_	_	RB	_	_	_	_	_
32	would	_	_	MD	_	_	_	_	_
33	change	_	_	VB	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	oral	_	_	JJ	_	_	_	_	_
36	absorbed	_	_	VBN	_	_	_	_	_
37	fraction	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	CYP3A4	_	_	NNP	_	_	_	_	_
6	isoenzyme	_	_	NN	_	_	_	_	_
7	increases	_	_	VBZ	_	_	_	_	_
8	expression	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	activity	_	_	NN	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	age	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	CYP3A4	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	practically	_	_	RB	_	_	_	_	_
4	undetectable	_	_	JJ	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	neonates	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	its	_	_	PRP$	_	_	_	_	_
10	expression	_	_	NN	_	_	_	_	_
11	increases	_	_	VBZ	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	age	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	reaching	_	_	VBG	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	maximum	_	_	JJ	_	_	_	_	_
18	level	_	_	NN	_	_	_	_	_
19	at	_	_	IN	_	_	_	_	_
20	two	_	_	CD	_	_	_	_	_
21	years	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	age	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Likewise	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	these	_	_	DT	_	_	_	_	_
5	age	_	_	NN	_	_	_	_	_
6	groups	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	there	_	_	EX	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	immature	_	_	JJ	_	_	_	_	_
11	intestinal	_	_	JJ	_	_	_	_	_
12	activity	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	alkaline	_	_	JJ	_	_	_	_	_
15	phosphatase	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	glucuronidation	_	_	NN	_	_	_	_	_
18	enzymes	_	_	NNS	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	carboxylesterase-2	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Conversely	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	no	_	_	DT	_	_	_	_	_
6	differences	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	p-glycoprotein	_	_	NN	_	_	_	_	_
9	expression	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	most	_	_	RBS	_	_	_	_	_
13	studied	_	_	VBN	_	_	_	_	_
14	intestinal	_	_	JJ	_	_	_	_	_
15	efflux	_	_	NN	_	_	_	_	_
16	transporter	_	_	NN	_	_	_	_	_
17	from	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	earliest	_	_	JJS	_	_	_	_	_
20	stages	_	_	NNS	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	life	_	_	NN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	adults	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Many	_	_	JJ	_	_	_	_	_
2	drugs	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	formulated	_	_	VBN	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	pharmaceutical	_	_	JJ	_	_	_	_	_
7	forms	_	_	NNS	_	_	_	_	_
8	that	_	_	WDT	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	often	_	_	RB	_	_	_	_	_
11	not	_	_	RB	_	_	_	_	_
12	appropriate	_	_	JJ	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	pediatrics	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	such	_	_	JJ	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	tablets	_	_	NNS	_	_	_	_	_
19	or	_	_	CC	_	_	_	_	_
20	capsules	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Children	_	_	NNS	_	_	_	_	_
2	need	_	_	VBP	_	_	_	_	_
3	different	_	_	JJ	_	_	_	_	_
4	oral	_	_	JJ	_	_	_	_	_
5	dosage	_	_	NN	_	_	_	_	_
6	formulations	_	_	NNS	_	_	_	_	_
7	from	_	_	IN	_	_	_	_	_
8	adults	_	_	NNS	_	_	_	_	_
9	mainly	_	_	RB	_	_	_	_	_
10	due	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	their	_	_	PRP$	_	_	_	_	_
13	developmental	_	_	JJ	_	_	_	_	_
14	capabilities	_	_	NNS	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	swallowing	_	_	VBG	_	_	_	_	_
17	ability	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	palatability	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	dosage	_	_	NN	_	_	_	_	_
22	requirements	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Especially	_	_	RB	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	pediatrics	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	palatability	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	closely	_	_	RB	_	_	_	_	_
8	related	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	acceptance	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	adherence	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Consequently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	bitterness	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	trigeminal	_	_	JJ	_	_	_	_	_
6	irritation	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	perceptible	_	_	JJ	_	_	_	_	_
9	malodors	_	_	NNS	_	_	_	_	_
10	must	_	_	MD	_	_	_	_	_
11	be	_	_	VB	_	_	_	_	_
12	minimized	_	_	VBN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	increasing	_	_	VBG	_	_	_	_	_
3	need	_	_	NN	_	_	_	_	_
4	for	_	_	IN	_	_	_	_	_
5	age-related	_	_	JJ	_	_	_	_	_
6	medicines	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	pediatrics	_	_	NNS	_	_	_	_	_
9	could	_	_	MD	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	met	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	extemporaneous	_	_	JJ	_	_	_	_	_
14	formulations	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	compounding	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	an	_	_	DT	_	_	_	_	_
5	extemporaneous	_	_	JJ	_	_	_	_	_
6	formula	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	not	_	_	RB	_	_	_	_	_
9	allowed	_	_	VBN	_	_	_	_	_
10	if	_	_	IN	_	_	_	_	_
11	an	_	_	DT	_	_	_	_	_
12	authorized	_	_	VBN	_	_	_	_	_
13	commercial	_	_	JJ	_	_	_	_	_
14	pharmaceutical	_	_	NN	_	_	_	_	_
15	product	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	adequate	_	_	JJ	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	particular	_	_	JJ	_	_	_	_	_
21	age	_	_	NN	_	_	_	_	_
22	group	_	_	NN	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	exists	_	_	VBZ	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	but	_	_	CC	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	reality	_	_	NN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	clinical	_	_	JJ	_	_	_	_	_
32	setting	_	_	NN	_	_	_	_	_
33	is	_	_	VBZ	_	_	_	_	_
34	that	_	_	IN	_	_	_	_	_
35	for	_	_	IN	_	_	_	_	_
36	some	_	_	DT	_	_	_	_	_
37	age	_	_	NN	_	_	_	_	_
38	groups	_	_	NNS	_	_	_	_	_
39	,	_	_	,	_	_	_	_	_
40	that	_	_	DT	_	_	_	_	_
41	is	_	_	VBZ	_	_	_	_	_
42	not	_	_	RB	_	_	_	_	_
43	the	_	_	DT	_	_	_	_	_
44	case	_	_	NN	_	_	_	_	_
45	,	_	_	,	_	_	_	_	_
46	while	_	_	IN	_	_	_	_	_
47	extemporaneous	_	_	JJ	_	_	_	_	_
48	formulation	_	_	NN	_	_	_	_	_
49	is	_	_	VBZ	_	_	_	_	_
50	still	_	_	RB	_	_	_	_	_
51	used	_	_	VBN	_	_	_	_	_
52	as	_	_	IN	_	_	_	_	_
53	the	_	_	DT	_	_	_	_	_
54	only	_	_	JJ	_	_	_	_	_
55	alternative	_	_	NN	_	_	_	_	_
56	to	_	_	TO	_	_	_	_	_
57	the	_	_	DT	_	_	_	_	_
58	therapeutic	_	_	JJ	_	_	_	_	_
59	need	_	_	NN	_	_	_	_	_
60	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	solid	_	_	JJ	_	_	_	_	_
3	products	_	_	NNS	_	_	_	_	_
4	have	_	_	VBP	_	_	_	_	_
5	higher	_	_	JJR	_	_	_	_	_
6	stability	_	_	NN	_	_	_	_	_
7	than	_	_	IN	_	_	_	_	_
8	liquid	_	_	JJ	_	_	_	_	_
9	formulations	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	this	_	_	DT	_	_	_	_	_
12	practice	_	_	NN	_	_	_	_	_
13	can	_	_	MD	_	_	_	_	_
14	solve	_	_	VB	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	problem	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	swallowing	_	_	VBG	_	_	_	_	_
19	capability	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	dose	_	_	NN	_	_	_	_	_
22	adjustments	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	but	_	_	CC	_	_	_	_	_
25	these	_	_	DT	_	_	_	_	_
26	manufactured	_	_	VBN	_	_	_	_	_
27	preparations	_	_	NNS	_	_	_	_	_
28	can	_	_	MD	_	_	_	_	_
29	be	_	_	VB	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	risk	_	_	NN	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	safety	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	efficacy	_	_	NN	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	quality	_	_	NN	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	because	_	_	IN	_	_	_	_	_
40	there	_	_	EX	_	_	_	_	_
41	is	_	_	VBZ	_	_	_	_	_
42	little	_	_	JJ	_	_	_	_	_
43	or	_	_	CC	_	_	_	_	_
44	no	_	_	DT	_	_	_	_	_
45	information	_	_	NN	_	_	_	_	_
46	for	_	_	IN	_	_	_	_	_
47	compatibility	_	_	NN	_	_	_	_	_
48	between	_	_	IN	_	_	_	_	_
49	the	_	_	DT	_	_	_	_	_
50	original	_	_	JJ	_	_	_	_	_
51	medicine	_	_	NN	_	_	_	_	_
52	and	_	_	CC	_	_	_	_	_
53	additional	_	_	JJ	_	_	_	_	_
54	excipients	_	_	NNS	_	_	_	_	_
55	or	_	_	CC	_	_	_	_	_
56	their	_	_	PRP$	_	_	_	_	_
57	effect	_	_	NN	_	_	_	_	_
58	in	_	_	IN	_	_	_	_	_
59	children	_	_	NNS	_	_	_	_	_
60	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	excipients	_	_	NNS	_	_	_	_	_
3	used	_	_	VBN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	formulations	_	_	NNS	_	_	_	_	_
6	designed	_	_	VBN	_	_	_	_	_
7	for	_	_	IN	_	_	_	_	_
8	children	_	_	NNS	_	_	_	_	_
9	should	_	_	MD	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	appropriate	_	_	JJ	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	each	_	_	DT	_	_	_	_	_
14	age	_	_	NN	_	_	_	_	_
15	group	_	_	NN	_	_	_	_	_
16	because	_	_	IN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	known	_	_	VBN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	these	_	_	DT	_	_	_	_	_
23	are	_	_	VBP	_	_	_	_	_
24	not	_	_	RB	_	_	_	_	_
25	inert	_	_	JJ	_	_	_	_	_
26	substances	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	cannot	_	_	MD	_	_	_	_	_
29	be	_	_	VB	_	_	_	_	_
30	supposed	_	_	VBN	_	_	_	_	_
31	to	_	_	TO	_	_	_	_	_
32	have	_	_	VB	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	same	_	_	JJ	_	_	_	_	_
35	effects	_	_	NNS	_	_	_	_	_
36	in	_	_	IN	_	_	_	_	_
37	pediatrics	_	_	NNS	_	_	_	_	_
38	as	_	_	IN	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	adults	_	_	NNS	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	most	_	_	RBS	_	_	_	_	_
3	common	_	_	JJ	_	_	_	_	_
4	example	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	early	_	_	JJ	_	_	_	_	_
7	stage	_	_	NN	_	_	_	_	_
8	children	_	_	NNS	_	_	_	_	_
9	who	_	_	WP	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	not	_	_	RB	_	_	_	_	_
12	able	_	_	JJ	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	metabolize	_	_	VB	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	eliminate	_	_	VB	_	_	_	_	_
17	them	_	_	PRP	_	_	_	_	_
18	as	_	_	IN	_	_	_	_	_
19	adults	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	ideal	_	_	JJ	_	_	_	_	_
3	situation	_	_	NN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	development	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	pediatric	_	_	JJ	_	_	_	_	_
9	formulations	_	_	NNS	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	minimal	_	_	JJ	_	_	_	_	_
13	use	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	added	_	_	VBN	_	_	_	_	_
16	excipients	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	both	_	_	CC	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	number	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	quantity	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_

